

1 Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate
2 dengue vaccines.

3 Pierce KK^{1*}, Whitehead SS², Diehl SA³, Naro G³, Carmolli MC³, He H⁴, Tibery, CM⁵, Sabundayo BP⁴,
4 Kirkpatrick BD^{1,3}, Durbin AP⁴.

5 Vaccine Testing Center, Departments of Medicine¹ and Microbiology and Molecular Genetics³,
6 University of Vermont Larner College of Medicine, Burlington, Vermont, ²National Institute of Allergy
7 and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, ⁴Johns Hopkins Bloomberg
8 School of Public Health, Baltimore, Maryland, ⁵Currently at National Institutes of Health, Bethesda,
9 Maryland

10 *Corresponding Author: Kristen K. Pierce

11 Email: Kristen.pierce@uvmhealth.org

12 Word Count: Abstract=59, text=1752

13

14 Abstract:

15 All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must
16 protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue
17 serotype 3 (rDEN30Δ30) was developed. All challenge virus recipients safely met the primary endpoint
18 of viremia and secondary endpoints of rash and seroconversion to DENV-3.

19 Keywords: Controlled Human Infection Model, Dengue, Vaccine

20 Running title: DENV-3 controlled human infection model

21

22

23

24 Background

25 Infections caused by dengue virus (DENV) are among the most prevalent mosquito borne diseases
26 globally. The World Health Organization (WHO) estimates that dengue viruses cause over 50 million
27 cases of dengue fever (DF) and 500,000 cases of severe disease: dengue hemorrhagic fever or dengue
28 shock syndrome, annually [1]. Effective therapeutic agents for dengue disease do not exist, making
29 vaccine development vital. Disease can be caused by any of four serotypes, DENV1-4, which complicates
30 vaccine development. Infection with one serotype confers long lasting homotypic (serotype-specific)
31 clinical immunity and short-lived heterotypic immunity to the other three serotypes. Although severe
32 disease can occur following primary infection, studies have shown that most severe dengue cases occur
33 in subsequent infections with a serotype different (heterotypic) from the first infection [2]. This
34 phenomenon is thought to be mediated by antibody dependent enhancement of infection (ADE):
35 whereby non-neutralizing antibody from the primary serotype binds but cannot neutralize the second
36 infecting serotype, leading to enhanced cellular entry via the Fcγ receptor and viral replication [3]. For
37 this reason, an ideal dengue vaccine would achieve a homotypic response to all four serotypes.

38 Several live attenuated tetravalent dengue vaccines are in development. The only licensed vaccine,
39 Dengvaxia®, remains limited in its use due to excess levels of dengue hospitalization following a
40 subsequent dengue infection in individuals who were dengue sero-naïve at vaccination [4, 5].

41 Given these safety concerns, testing of candidate vaccines in humans must be done with great caution.

42 Human infection models are an established tool for early evaluation of vaccine efficacy. The dengue
43 controlled human infection model (D-CHIM) developed by our team uses well-studied, naturally

44 attenuated dengue strains to elicit safe, low-level dengue infection in healthy volunteers. Our D-CHIM is
45 an infection model with viremia and rash as clinical endpoints rather than a disease model which
46 induces symptomatic illness. To use the D-CHIM for vaccine candidate evaluation, individuals receive a
47 dengue vaccine or placebo and are subsequently inoculated with the challenge strain to determine the
48 protection provided by vaccination. Our first D-CHIM used a recombinant DENV-2 (Tonga) as the
49 challenge strain to assess the protective efficacy of the TV003 vaccine. Six months after vaccination,
50 TV003 elicited complete protection against DENV-2 challenge, whereas all placebo recipients
51 demonstrated infectious DENV-2 (Tonga) viremia following challenge [6].

52 The success of the DENV-2 D-CHIM compelled us to develop challenge strains for the other DENV
53 serotypes to evaluate the broad protective efficacy of the NIH tetravalent vaccines, TV003 and TV005.
54 We developed a recombinant DENV-3 challenge strain, rDEN3Δ30, for use in D-CHIM studies of
55 candidate dengue vaccines.

56 DENV-3 Sleman/78 is the parent virus for both the attenuated DENV-3 (rDEN30Δ30/31) vaccine
57 component of TV003 and TV005 and the rDEN3Δ30 challenge strain described herein. DENV-3
58 Sleman/78 was isolated during a dengue outbreak in 1978 in the Sleman district in Central Java [7].
59 During that year, illness was mild, mostly observed in children under 15 years of age, with no dengue
60 associated deaths. In contrast, the DENV-3 strain (Bantul), which had circulated the previous year, led to
61 significant illness and hospitalization. The viremia for the Sleman strain was lower than the previous
62 Bantul strain and is considered to be naturally attenuated. The rDEN3Δ30 virus was originally developed
63 as a candidate DENV-3 vaccine. However, in nonhuman primate models, rDEN3Δ30 was not significantly
64 attenuated compared to the parent virus DENV-3 Sleman/78 [8]. rDEN3Δ30 induced viremia in 100% of
65 rhesus macaques with a mean peak titer of $1.5 \log_{10}$ PFU/mL compared to 75% of rhesus macaques who
66 were viremic with a mean peak virus titer of $2.0 \log_{10}$ PFU/mL following inoculation with the parent virus
67 DENV-3 Sleman/78.

68 Here we describe the first evaluation of rDEN3Δ30 in healthy, flavivirus-naïve human volunteers and the
69 potential for its use in future D-CHIM studies.

70 Methods

71 This study was conducted under IND application (IND # 16765) at the Center for Immunization Research,
72 Johns Hopkins School of Public Health and the Vaccine Testing Center, University of Vermont College of
73 Medicine, and was approved by their Institutional Review Boards and Biosafety Committees. The
74 National Institute of Allergy and Infectious Diseases (NIAID) Intramural Data Safety Monitoring Board
75 reviewed all study data. Clinicaltrials.gov NCT02684383.

76 Study population. Volunteers were recruited from Baltimore, MD, and Burlington, VT. Informed consent
77 was obtained. Similar to previously published studies, inclusion criteria included: healthy subjects age
78 18-50, negative serology for Hepatitis B, C and HIV, no evidence of prior dengue infection or other
79 flaviviruses, and normal screening values for liver and renal function, urinalysis and coagulation [9].
80 Women of childbearing potential had a negative pregnancy test at screening and on inoculation day and
81 were required to use a reliable method of contraception for study duration. Following receipt of the
82 test article (rDEN3Δ30 or placebo), subjects recorded their temperature three times daily.

83 Study design

84 A randomized double-blind controlled trial was performed with 14 subjects. Randomization was 5:2, to
85 receive either 3 log₁₀ PFU of rDEN3Δ30 or placebo (L-15) as a 0.5 mL subcutaneous injection. To
86 adequately power for viremia only 10 subjects were required to receive DENV-3. Following dosing,
87 volunteers returned to the clinic every other day for the first 2 weeks and then on study days 21, 28, 56,
88 90, and 180 for clinician assessment, which included physical exam and documentation of clinical signs
89 and symptoms. During the first 2 weeks volunteers were contacted via phone on non-clinic days to
90 review symptoms and to check for fever. During clinic visits, blood was obtained for virus titration and

91 safety laboratory studies (CBC, ALT, coagulation studies). Neutralizing antibody was measured at days 0
92 (pre-vaccination), 28, 56, 90 and 180 using the 50% plaque reduction neutralization titer (PRNT₅₀) assay
93 with DENV-3 Sleman/78 as the target virus [10]. Seroconversion was defined as \geq 4-fold rise in
94 neutralizing antibody titer at day 90 compared to day 0. Viremia was assessed as described using
95 culture-based method [10]. The frequency of clinical signs and symptoms was compared between
96 rDEN3 Δ 30 and placebo recipients and their statistical significance was determined using Fisher's Exact
97 test.

98 Results

99 14 subjects were enrolled, five (35%) were women. At each site five subjects received rDEN3 Δ 30 and
100 two subjects received placebo (diluent). Mean age was 34 years (range 24-47 years).

101 All 10 subjects who received rDEN3 Δ 30 (100%) met the primary endpoint of viremia and 8 (80%) had a
102 dengue-like rash. Rash was only seen in rDEN3 Δ 30 recipients and was dengue-like in appearance
103 (diffuse, maculopapular, and present over the trunk and extremities). It was observed approximately
104 four days after challenge, and completely resolved within 7-10 days. Among the eight rash
105 presentations, five were graded as moderate and three were mild. Transient, asymptomatic neutropenia
106 and thrombocytopenia were seen in one and two volunteers, respectively.

107 Individual viremia data are presented in Figure 1A. The mean peak viremia titer in rDEN3 Δ 30 recipients
108 was 1.8 log₁₀ PFU/mL (range 0.5-2.1); mean day of onset was 4.6 days (range 3-6 days) with a mean
109 duration of 3.4 days. All 10 rDEN3 Δ 30 recipients seroconverted to DENV-3; the PRNT₅₀ to DENV-3
110 peaked at day 28. Although titers declined slightly, they remained high at day 180 with a GMT of 143
111 (range 44-392). Peak low level heterotypic antibodies to serotypes DENV-1 and -2 were seen in
112 rDEN3 Δ 30 recipients (**Figure 1B**).

113 Overall, the DENV-3 inoculation was well-tolerated. Fever was not observed in any volunteer. Local
114 reactogenicity in the rDEN3Δ30 group included injection site erythema (10%) and injection site
115 induration (20%). The frequency of clinical signs and symptoms other than rash were not significantly
116 different between the groups (**Table 1**). Of the 86 reported events, 77 (89.5%) were considered mild;
117 the remainder were graded as moderate. The only moderate events deemed to be related to rDEN3Δ30
118 or placebo were rash and fatigue.

119 Discussion

120 Important requirements for development of a safe dengue vaccine include the need to achieve a robust
121 and balanced immune response protective against all four serotypes while maintaining an acceptable
122 reactogenicity profile. The implication of an incomplete or imbalanced response, as recently seen in
123 long-term follow up of Dengvaxia® recipients, is the possibility the vaccine may predispose to more
124 severe disease upon subsequent exposure to DENV years following vaccination [4]. Although
125 neutralizing antibody is thought to be a mediator of protection, titers of neutralizing antibody induced
126 by Dengvaxia® were not indicative of protection against dengue [11]. Use of the D-CHIM to evaluate the
127 protective efficacy of candidate vaccines offers additional assurances of serotype-specific protection in
128 advance of phase III testing in large endemic-setting populations.

129 Our study demonstrated rDEN3Δ30 is highly infectious and immunogenic yet induces mild to moderate
130 clinical signs in all inoculated volunteers. The infectivity and safety profile of the DENV-3 challenge virus
131 makes it ideal for use in CHIM studies to evaluate candidate vaccines. As seen in the DENV-2 CHIM, we
132 targeted induction of detectable viremia in a high percentage of subjects, with peak titers that elicited
133 only mild to moderate clinical signs [6]. Prior to our model, another research team performed a Dengue
134 3 CHIM as a disease model which caused symptomatic dengue-like illness. Volunteers in that study
135 experienced fever for several days, transaminitis, and one subject had evidence of perihepatic and

136 pericardial effusions by ultrasound [12]. In our study, 100% of rDEN3Δ30 recipients had detectable
137 viremia and seroconverted to DENV-3 based on neutralizing antibody; dengue-like rash was seen in
138 eight of 10 volunteers (80%). Neither fever, transaminitis, nor effusions were observed in any volunteer.
139 Given that 75% of DENV infections do not present for clinical care, we propose that the endpoints of
140 viremia and rash are relevant to the course of natural infection and are reproducible targets upon which
141 candidate vaccines can be safely evaluated.

142 When compared to our DENV-2 D-CHIM, rDEN3Δ30 infection induced a lower mean peak virus titer
143 ($1.77 \log_{10}$ PFU/mL) vs. rDEN2Δ30 ($2.3 \log_{10}$ PFU/mL). Nevertheless, rDEN3Δ30 induced rashes of
144 moderate severity in 50% of challenge volunteers. This possible disconnect of peak viremia titer and
145 rash severity will be monitored closing in subsequent trials.

146 The rDEN3Δ30 CHIM is an important new tool for evaluating candidate dengue vaccines in advance of
147 phase III efficacy trials in endemic populations. Its safety and infectivity profiles are acceptable and
148 because of rDEN3Δ30's high infectivity, efficacy studies can be powered for significance with relatively
149 few subjects. We argue that, in light of the concerns raised with the most recent large scale Phase III
150 dengue vaccine trials, the CHIM provides a platform to test vaccine safety and efficacy on a smaller scale
151 before large scale vaccine roll out. This DENV-3 CHIM is currently being used to evaluate the efficacy of
152 the TV005 vaccine to protect against infection with rDEN3Δ30 at 6 months post-vaccination.

153

154 Funding

155 This work was supported by the National Institute of Allergy and Infectious Disease Intramural Research
156 Program, National Institutes of Health [contract no. HHSN272200900010C]

157

158 Acknowledgments

159 Dengue virus strains were provided by the Laboratory of Infectious Diseases, NIH. We would like to
160 thank all of the dedicated volunteers, and the excellent research nurses and staff at the JHU CIR and
161 UVM VTC Clinical Research Centers. In addition, the authors would like to thank the Office of Clinical
162 Research Policy and Regulatory Operations at the NIH for providing the regulatory oversight.

163 Potential Conflicts of Interest

164 None of the above authors have any reported conflict of interest. All authors have submitted the ICMJE
165 form for potential conflicts of interest. Conflicts that the editors of the manuscript consider relevant to
166 the content of the manuscript have been disclosed.

167

168 FIGURE LEGEND

169 **Figure 1 (A)** rDEN3Δ30 was cultured from serum samples collected on the indicated days. Virus was
170 detected by culture in Vero cells as described in the methods. Time course of viremia for the 10
171 individuals administered rDEN3Δ30 is shown. The lower limit of detection is $0.5 \log_{10}$ PFU/mL of serum.
172 PFU, plaque forming unit. **(B)** Serum was collected from the 10 infected individuals on study days 0, 28,
173 56, 90, and 180. The peak PRNT₅₀ achieved through study day 90 for each of the four DENV serotypes is
174 shown for all individuals who developed a PRNT₅₀ > 1:5 (limit of detection). The geometric mean peak
175 titer with SD is indicated.

176

177

178

179


180

181

182


183

184 Figure 1A:



185

186 Figure 1B:



187

188

189

190 Table 1: Clinical signs and symptoms following a single dose of rDEN3Δ30 compared with placebo

	DEN3Δ30 (n=10)	Placebo (n=4)	p-value (1-sided) ^a
Local			
Erythema	10.0%	0.0%	0.7143
Tenderness	0.0%	0.0%	n/a
Pain	0.0%	0.0%	n/a
Pruritus	0.0%	0.0%	n/a
Induration	20.0%	0.0%	0.4945
Systemic			
Viremia	100.0%	0.0%	0.0010
Fever	0.0%	0.0%	n/a
Headache	60.0%	75.0%	0.8741
Rash	80.0%	0.0%	0.0150
Neutropenia ^b	10.0%	0.0%	0.7143
Elevated ALT	0.0%	0.0%	n/a
Myalgia	40.0%	25.0%	0.5455
Arthralgia	10.0%	0.0%	0.7143
Retro-orbital Pain	50.0%	25.0%	0.4056
Photophobia	10.0%	25.0%	0.9341
Fatigue	50.0%	50.0%	0.7203
Nausea	10.0%	50.0%	0.9890
Prolonged PT	0.0%	0.0%	n/a
Prolonged PTT	0.0%	0.0%	n/a
Hemoglobin Decreased	10.0%	0.0%	0.7143
Thrombocytopenia ^c	20.0%	0.0%	0.4945

191 ^{a.} Fisher's Exact test, p value not corrected for multiple comparisons

192 ^{b.} Neutropenia was defined as an ANC $\leq 1,000/\text{mm}^3$

193 ^{c.} Thrombocytopenia was defined as $\leq 120,000/\text{mm}^3$

194

195

196

197

198

199

200

201 References

202 1. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva:
203 WHO, **1997**.

204 2. Monath T, Heinz F. Flaviviruses. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields Virology. third
205 ed. Vol. 1. Philadelphia: Lipincott-Raven, **1996**:961-1034.

206 3. Halstead SB, Chow J, Marchette NJ. Immunologic enhancement of dengue virus replication. Nature
207 New Biology **1973**; 243:24-6. PMID:

208 4. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and
209 Efficacy. N Engl J Med **2018**; 379:327-40. PMID: 29897841.

210 5. Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent
211 dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled
212 trial. The Lancet **2014**; 384:1358-65. PMID: 25018116.

213 6. Kirkpatrick BD, Whitehead SS, Pierce KK, et al. The live attenuated dengue vaccine TV003 elicits
214 complete protection against dengue in a human challenge model. Sci Transl Med **2016**; 8:330ra36.
215 PMID: 27089205.

216 7. Gubler DJ, Suharyono W, Lubis I, Eram S, Gunarso S. Epidemic dengue 3 in central Java, associated
217 with low viremia in man. Am J Trop Med Hyg **1981**; 30:1094-9. PMID:

218 8. Blaney JE, Jr., Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified,
219 live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg **2004**; 71:811-21. PMID:
220 15642976.

221 9. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus
222 type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg
223 **2001**; 65:405-13. PMID: 11716091.

224 10. Durbin AP, Kirkpatrick BD, Pierce KK, et al. A Single Dose of Any of Four Different Live Attenuated
225 Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-
226 blind Clinical Trial. J Infect Dis **2013**; 207:957-65. PMID: 23329850. 3571448.

227 11. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-
228 attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b
229 trial. Lancet **2012**; 380:1559-67. PMID: 22975340.

230 12. Lyons AG. The Human Dengue Challenge Experience at the Walter Reed Army Institute of Research.
231 Journal of Infectious Diseases **2014**; 209:S49-S55. PMID:

